CEO Insights Magazine

Responsible for playing a pivotal role amidst the COVID-19 pandemic, the pharmaceutical and life sciences sector is brimming with new possibilities. To cope with the ongoing and upcoming healthcare crisis across the world, many countries have accelerated their research and adopted novel technological advancements to develop the cutting-edge medicines and vaccines in history. Supplying over 50 percent of global demand for various vaccines, including 40 percent of basic demand across the US and 25 percent of all medicines in the UK, India is currently positioned as the largest provider of generic drugs globally. Worldwide, India ranks third in terms of medicinal production by volume and 14th by value. In India, the domestic pharmaceutical sector includes a massive network of 3,000 drug companies and approx. 10,500 manufacturing units. Equipped with a large pool of scientists, engineers, and industry stalwarts having the potential to navigate the industry ahead to greater summits, India is enjoying a significant position in the global pharmaceuticals sector.

"For us, success does n’t lie in the figures or statistics, but in curing the maximum number of people we can and we are never going to stop"

One such phenomenon is Dilip Jain (Foundar & Chairman, Johnlee Pharmaceuticals), who has maneuvered the foundation and evolution of his firm Johnlee Pharma ceuticals as one of the exceptionally managed and exponentially growing pharmaceutical companies having more than seven years of manufacturing and marketing experience. During his more than 16 years of experience in the Pharma industry as an industry leader, Dilip garnered a wide range of expertise in sales, marketing, and creating distribution networks on a Pan India basis. Implementing his acquired professional skills to lay a strategic grid that ultimately catapulted the evolution of Johnlee Pharmaceuticals as a leading brand of pharmaceutical and life sciences domain, Dilip has led the firm to focus in high growth potential segments like Vaccines and Biogenetics.

Engaging in an exclusive interaction with CEO Insights, Dilip highlights the nuances of his journey across the pharmaceutical industry of India as a promising leader of the segment.

Highlight the current roles and responsibilities undertaken by you at Johnlee Pharmaceuticals? How are you leveraging your expertise to help the company succeed in the

longrun?
Currently, I am managing the company’s overall responsibilities with maximum capacity. But to be able to attain such optimal responsibility, a person needs to learn how to leverage his time, as well as that of other people’s time. Apart from that, I have got prolific expertise in project planning, management skills, resources, knowledge & education, and technology, innovation and all of these traits play a prominent part in my present day operations.

How would you define Johnlee Pharma ceuticals as an organization and its position in the market?
Johnlee Pharmaceutical is currently positioned at the top 10 developing Pharma companies in India. Based in Mumbai, Maharashtra the company has been accredited with ISO-9001: 2015 and manufactures Pharmaceutical formulations as per the guidelines of WHO. We are working towards technology and innovative ideas to make medicine reach the common people at an affordable cost.

Focusing on our clients as well as their top priorities such as quality products, on time delivery, competitive rates, and unparalleled responsiveness, we have managed to achieve success in our journey so far. Manufacturing more than 400 pharmaceutical formulation products in the form of tablets, capsules, dry syrup, liquid orals, and sustained release preparations, we also excessively focus on high growth potential segments like Vaccines and Biogenetics. We believe that these new areas will add significant depth to the existing product pipeline. For example, proteasome has been authenticated as an imperative clinical target in cancer. Intending to increase therapeutic efficacy and reduce side effects, Johnlee Pharmaceuticals is producing next generation proteasome inhibitors with a high degree of selectivity.

What makes your firm different from other co players within the industry?
Always devoted to upholding the best quality in the formulation and products, our medicines are manufactured under the strict supervision of experienced and talented chemists. Being equipped with team members who have vast knowledge about medicine formulation and its protocols makes

our operation easy and guarantees us to deliver bulk orders within the promised period. Covering a vast field of medicines such as Antibacterial, Antidiabetics, Analgesics, Antifungals Antipsychotics, Antiasthmatics, Antacids, Antimalarials, Cardiovascular, Cosmeceuticals, Gastro intestinal, SkinCare, Psychotropic and Nutraceuticals, we have been successful in carving our name as an eminent manu facturer and exporter within the industry.

What are the changes in market behaviour that you anticipate, and what are the opportunities that you foresee at present? What are your future goals according to that?
With every individual trying to learn self care and taking care of their health in many ways, I could envisage the industry switching to pre-vitamins and protein products. This is a good aspect on which every pharmaceutical firm should focus. India is a country where people love to get indulged in major junk food & drinks. The number, as well as the variants of the diseases are increasing. This will create the demand for advanced and innovative medicine compositions, resulting in the ultimate growth of the pharma industry. Our future goal is to make our company amongst the most trusted pharmaceutical conglomerates in the world. For us, success doesn’t lie in the figures or statistics, but in curing the maximum number of people we can and we are never going to stop.

In the light of your strong experience in the pharma domain, what advice would you give to budding entrepreneurs?
The only piece of advice that I would like to share is ‘the competition has to be healthy’. Functioning in the healthcare industry itself becomes a huge responsi bility, and we as players should ensure that we follow proper work ethics to succeed.

Dilip Jain, Director, Johnlee Pharmaceuticals
Starting his professional journey in 2000 with a job in the Pharmaceutical Industry, Dilip started his own firm Ambica Pharma in 2005 as a first generation entrepreneur. In 2011, he played a pragmatic role in the establishment of Johnlee Pharmaceuticals, a Generics company that manufactures & sells pharmaceutical generics, formulations and nutraceuticals across India as well as at an international level.

Hobbies: Reading Books, Travelling, and Going to the gym
Favorite Cuisine: Wada Pav, PaniPuri
Favorite Book: Rich Dad and Poor Dad
Favorite Travel Destination:
Switzerland

Awards & Recognition:
i.Iconic Indian Generic Pharma from MIDDAY
ii.Excellence in Affordable Healthcare from ZEE 24 TAAS